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doi:10.1Objective:We investigated the impact of preoperative pulmonary hypertension (PH) on early and late outcomes
after mitral valve operation for mitral regurgitation.
Methods: Systolic pulmonary artery pressure (sPAP) was measured before operation in 873 consecutive patients
who underwent mitral valve surgery for mitral regurgitation between January 2002 and January 2010. PH was
classified as none (sPAP<40 mm Hg), mild (40 sPAP<50 mm Hg), moderate (50 sPAP<60 mm Hg), or
severe (sPAP  60 mm Hg).
Results: Increased preoperative sPAP was associated with greater left ventricular dysfunction and dilation, left
atrial enlargement, more atrial fibrillation, and tricuspid regurgitation. Operative mortality was correlated with
the degree of preoperative PH (2%, 3%, 8%, and 12% for none, mild, moderate, and severe PH, respectively,
P<.0001). Long-term survival was related to preoperative sPAP (5-year survival: 88%, 79%, 65%, and 53%
for none, mild, moderate, and severe PH, respectively; P<.0001). In multivariable analyses, sPAP was a predic-
tor of both operative mortality (odds ratio, 1.023 per 1 mm Hg increase; 95% confidence interval, 1.003–1.044;
P ¼ .0270) and late death (hazard ratio, 1.018 per 1 mm Hg increase; 95% confidence interval, 1.007–1.028;
P ¼ .001). Among 284 patients with isolated degenerative mitral regurgitation due to leaflet prolapse, actuarial
survival was 97.5%, 91.2%, and 80.5% for none, mild, and moderate to severe PH, respectively (P ¼ .0002).
Conclusions: Preoperative sPAP is a powerful predictor of early and late survival after mitral valve operation for
mitral regurgitation. Evenmodest increases in sPAP adversely affect outcomes. Mitral valve operation should be
performed before the development of PH. (J Thorac Cardiovasc Surg 2011;142:1439-52)A
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DPulmonary hypertension (PH) is common among patients
referred for mitral valve (MV) surgery for mitral regurgita-
tion (MR). Although it is generally acknowledged that the
presence of PH has a negative impact on operative out-
comes, available data are remarkably scant and generally
from small series.1-9 Current American College of
Cardiology/American Heart Association and European
Society for Cardiology guidelines recommend surgery for
asymptomatic patients with MR and resting systolic
pulmonary artery pressure (sPAP) greater than 50 mm Hg
as a class IIa recommendation based on level C evidence
(expert opinion).10,11 Pulmonary artery pressure is not
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The Journal of Thoracic and Carvalve surgery.12 The aim of the current study is to examine
the impact of PH on early and long-term survival in a large
cohort of patients undergoing surgery for MR.PATIENTS AND METHODS
From January 2002 to January 2010, 953 patients underwent MV sur-
gery for MR at the University of Maryland Medical Center. Patients
were identified using the local Society of Thoracic Surgeons clinical data-
base. This retrospective study was approved by the University of Maryland
institutional review board with patient consent waived (HP-00046760).
Preoperative, operative, and postoperative variables were collected. Pa-
tients with mitral stenosis, primary PH, and unrecorded sPAP (s) were ex-
cluded, leaving 873 patients for analysis (Figure 1). To assess the impact of
PH on patients undergoing primary operation for isolated degenerative MR
with leaflet prolapse,13 we examined a subset of 284 patients undergoing
primary isolated MV operation for leaflet prolapse (Figure 1). In cases in
which preoperative right heart catheterization (RHC) was performed, the
right atrial pressures, right ventricular pressures, pulmonary artery pres-
sures (PAPs), and pulmonary capillary wedge pressures were recorded. If
RHC was not performed, preoperative sPAP was measured with Doppler
echocardiography (modified Bernoulli equation: 43 [tricuspid regurgita-
tion jet velocity]2þright atrial pressure [10 mmHg]). sPAP was considered
equal to right ventricular systolic pressure in the absence of pulmonary ste-
nosis or right ventricular outflow tract obstruction.14 In cases in which the
sPAPwas available fromRHC and Doppler echocardiography, the RHC re-
sults were used. The left ventricular function and diameters and left atrial
(LA) dimensions and morphology of underlying MV disease were deter-
mined using Doppler echocardiography. The severity of valvular regurgita-
tion was assessed semiquantitatively on a scale of 0 to 4 (0¼ none or trace,diovascular Surgery c Volume 142, Number 6 1439
Abbreviations and Acronyms
CI ¼ confidence interval
LA ¼ left atrial
MR ¼ mitral regurgitation
MV ¼ mitral valve
NYHA ¼ New York Heart Association
OR ¼ odds ratio
PH ¼ pulmonary hypertension
RHC ¼ right heart catheterization
sBP ¼ systolic blood pressure
sPAP ¼ systolic pulmonary artery pressure
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D1 ¼ mild, 2 ¼ moderate, 3 ¼ moderate to severe, 4 ¼ severe).15 PH was
defined as sPAP 40 mmHg or greater. Patients were categorized as follows:
no PH (sPAP<40 mm Hg), mild PH (40 mm Hg  sPAP<50 mm Hg),
moderate PH (50 mm Hg  sPAP< 60 mm Hg), and severe PH (sPAP
 60 mm Hg). The ratio of sPAP over systemic systolic blood pressure
(sBP) was also measured. The mechanism of MR was determined on the
basis of preoperative echocardiography and intraoperative inspection.16
Operative mortality was defined as in-hospital mortality or death within
30 days of operation. Predischarge echocardiography was routinely per-
formed in a core echocardiography laboratory. Follow-up data including vi-
tal status and postoperative echocardiograms were obtained. Follow-up
echocardiography was obtained at as many time points as available for
each patient. A total of 1161 postoperative echocardiographic reports
were obtained from our echocardiographic laboratory or the patient’s refer-
ring cardiologist. sPAP data were analyzed during the following time pe-
riods: preoperatively, at discharge, during the first 2 years after surgery,
and after 2 years. The Social Security Death Master File was used to deter-
mine vital status.17 The status of all patients was assessed cross-sectionally
in May 2010. The mean follow-up time was 35 24 months, and the mean
duration of echocardiographic follow-up was 26  21 months.
The following questions were addressed:
1. What are the predictors of preoperative PH?
2. Did the presence of PH affect operative mortality and morbidity after
MVoperation?
3. What is the long-term survival after MV operation for MR in patients
with and without preoperative PH?
4. Does PH predict adverse short- and long-term outcome after MVoper-
ation for isolated degenerative MR?
5. Did pulmonary pressures regress over time after operation?
6. What is the best systolic pulmonary pressure cutoff point to minimize
early and late mortality after MVoperation for MR?
Statistical Analysis
Continuous variables are expressed as the mean  standard deviation
(for reasonably symmetric variables) or median with the interquartile range
(for clearly asymmetric variables). The values of categoric variables are ex-
pressed as proportions. Baseline compressions between patients’ character-
istics in different PH grades were performed using the chi-square test,
Fisher exact test, Student t test, Wilcoxon rank-sum test, and 1-way analy-
sis of variance where appropriate. In cohort 2 (patients with isolated degen-
erative MR), patients with moderate or severe PH were combined because
of the small number of both groups. Logistic regression analysis was used
(with variables listed in Appendix 1) to identify predictors of PH and oper-
ative mortality with a liberal retention criteria (P<.10 to enter and P>.10
to remove). The predicted probabilities of preoperative PH and operative
mortality were identified. Long-term survival was evaluated with the1440 The Journal of Thoracic and Cardiovascular SurKaplan–Meier method, and the log-rank test was used to compare the
groups. A Cox proportional hazard regression analysis was performed
for the determination of factors independently associated with long-term
survival. The odds ratio (OR) and hazard ratio (HR) for sPAP as a continu-
ous variable are displayed for 1 mm Hg increment. Receiver operating
characteristic curve analysis was performed to determine the cutoff values
that best predict early and late survival. Analysis was performed using JMP
8.0 statistical software (SAS Institute Inc, Cary, NC). All statistic tests were
2-sided, with an a level less than 0.05 for statistical significance.RESULTS
Patient Population
Between January 2002 and January 2010, 953 consecutive
MVoperations were performed at a single center. From this
total, 888 patients met the inclusion criteria (Figure 1).
sPAP was measured in 873 patients (98%) using RHC
(591, 68%) and echocardiography (282, 32%). The mean
patient age was 59  14 years. A total of 493 patients
(57%) were in New York Heart Association (NYHA) func-
tional class III or IV, and 260 patients (30%) had atrial fibril-
lation (Table 1). Moderate-to-severe or severe degree of MR
was present in 775 patients (89%). Right ventricular dys-
function defined as any degree of impairment in right ventric-
ular contraction was present in 137 of 873 patients (15%).Preoperative Characteristics and Pulmonary Artery
Pressure
sPAP was determined using RHC in 591 patients (68%)
(performed a mean of 29  45 days before operation). Av-
erage sPAP, mean pulmonary artery pressure, right atrial
pressure, right ventricular pressure, and pulmonary capil-
lary wedge pressure measured during RHC were 43  17
mm Hg, 29  12 mm Hg, 9  6 mm Hg, 11  8 mm Hg,
and 18 9mmHg, respectively. sPAPwas recorded on pre-
operative echocardiography in 621 patients (71%) (per-
formed a mean of 35  48 days before operation) with
a mean sPAP of 46  15 mm Hg. sPAP was measured in
373 patients with both echocardiography (mean  standard
deviation, 47 16 mm Hg) and RHC (mean standard de-
viation, 45  17 mm Hg). Measured mean sPAPs were not
significantly different between these 2 modalities (P ¼ .9).
A linear relationship was observed between the sPAPs re-
corded with echocardiography and RHC (r ¼ 0.39,
P<.0001).
PH (sPAP  40 mm Hg) was present in 466 patients
(53%) and was severe (sPAP  60 mm Hg) in 148 patients
(17%) (Table 2). We observed a temporal trend toward
a greater percentage of patients with no (sPAP< 40 mm
Hg) or mild (40  sPAP<50 mm Hg) PH undergoing sur-
gery over the course of the study. Higher preoperative
sPAPs were associated with increased age, female sex,
higher NYHA function class, and a greater prevalence of
comorbidities (Table 2). The mean left ventricular ejection
fraction decreased as sPAP increased, whereas the mean left
ventricular end-diastolic dimension was similar acrossgery c December 2011
TABLE 1. Selected preoperative patient characteristics for 873
patients undergoing mitral valve operation for mitral regurgitation
Characteristic No. (%), or mean ± SD
Age (y) 59  14
Female gender 361 (41%)
BMI (kg/m2) 27  7
NYHA class III/IV 493 (57%)
Atrial fibrillation 260 (30%)
Prior cardiac surgery 61 (7%)
Prior MV surgery 22 (3%)
Chronic lung disease 115 (13%)
Hypertension 561 (64%)
Diabetes mellitus 157 (18%)
Renal failure (dialysis) 50 (6%)
Cardiac structure, function
LV ejection fraction, mean,% 52  14
LA diameter, cm 4.6  0.8 (n* ¼ 641)
LV end-diastolic diameter, cm 5.4  0.8 (n ¼ 656)
LV end-systolic diameter, cm 3.8  0.9 (n ¼ 544)
sPAP (mm Hg)
Echocardiography 46  15 (n ¼ 621)
RHC 43  17 (n ¼ 591)
RV dysfunction 137 (15%)
MR grade
Moderate 98 (11%)
Moderate-to-severe 210 (24%)
Severe 565 (65%)
TR grade
None/mild 664 (76%)
Moderate 114 (13%)
Moderate-to-severe 36 (4%)
Severe 59 (7%)
AI grade
None/mild 787 (90%)
Moderate 44 (5%)
Severe 42 (5%)
Severe AS 49 (6%)
AI, Aortic insufficiency; AS, aortic stenosis; AV, aortic valve; BMI, body mass index;
LA, left atrium; LV, left ventricle; MR, mitral regurgitation;MV, mitral valve; NYHA,
New York Heart Association; RHC, right heart catheterization; RV, right ventricle;
SD, standard deviation; TR, tricuspid regurgitation; sPAP, systolic pulmonary artery
pressure. *Data available.
FIGURE 1. Patient population: exclusion criteria and final analysis pop-
ulation for cohort 1 and 2 studies. AV, Aortic valve; CABG, coronary artery
bypass graft surgery; MR, mitral regurgitation; MS, mitral stenosis; MV,
mitral valve; PPH, primary pulmonary hypertension; Redo, redo cardiac
surgery; sPAP, systolic pulmonary artery pressure.
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Dvarying levels of sPAP. Greater degrees of LA enlargement,
more atrial fibrillation, tricuspid regurgitation, systemic hy-
pertension, and RV dysfunction were present in patients
with higher preoperative sPAP. By multivariable analysis,
predictors that were significantly associated with higher
preoperative sPAP included female gender (OR, 2.88;
95% confidence interval [CI], 1.92–4.54; P<.0001), LA
dimension (OR, 1.05 per 1-mm increase; 95% CI, 1.03–
1.08; P< .0001), left ventricular end-systolic dimension
(OR, 1.05 per 1-mm increase; 95% CI, 1.03–1.08;
P < .0001), chronic lung disease (OR, 3.40; 95% CI,
1.70–7.70; P ¼ .0005), dialysis (OR, 7.86; 95% CI, 3.32–
33.38; P < .0001), previous myocardial infarction (OR,
2.37; 95% CI, 1.52–4.80; P¼ .0028), and body mass index
(OR, 1.05 per 1 kg/m2 increase; 95% CI, 1.02–1.09;
P ¼ .0017) (C-statistic ¼ 0.768).Operative Characteristics
Concomitant procedures performed included coronary
artery bypass in 253 patients (29%), tricuspid valve opera-
tion in 133 patients (15%), aortic valve operation in 100 pa-
tients (11%), and CryoMaze procedure in 185 patientsThe Journal of Thoracic and Car(21%). Sixty-one patients (7%) underwent redo operation
(Table 3). MV repair was performed in 747 patients
(86%), and MV replacement was performed in 126 patients
(14%). Operative characteristics as a function of preopera-
tive sPAP are summarized in Table 4. Patients with higher
sPAP more commonly required concomitant procedures.
MV repair was less commonly performed as the degree of
PH increased (repair rate 92% for no PH, 88% for mild
PH, 82% for moderate PH, and 70% for severe PH,
P<.0001) (Table 4).Operative Outcomes
The operative mortality rate for the entire population was
5% (n¼ 43, in hospital¼ 40). Operative mortality was 2%diovascular Surgery c Volume 142, Number 6 1441
TABLE 2. Baseline characteristics of the patient population according to degree of pulmonary hypertension*
Variable
sPAP<40 mm Hg
407 (47%)
40  sPAP<50 mm Hg
176 (20%)
50  sPAP<60 mm Hg
142 (16%)
sPAP  60 mm Hg
148 (17%) P value
sPAP (mm Hg)
Mean  SD 30  6 44  3 53  3 71  10 <.00001
Median (25th–75th percentile) 30 (25–35) 44 (41–46) 53 (50–55) 69 (63–77)
sPAP/sBP (mean  SD) 0.24  0.05 0.34  0.06 0.43  0.10 0.56  0.12 <.0001
Age (y) 58  14 61  13 61  15 62  14 .0048
Female gender 144 (35%) 82 (47%) 78 (45%) 71 (48%) .0008
BMI (kg/m2, mean  SD) 27  6 28  8 28  6 29  8 .0005
Morbid obesityy 16 (16%) 18 (31%) 8 (14%) 16 (28%) .2274
NYHA class III/IV 188 (46%) 102 (58%) 96 (68%) 107 (72%) .0001
Atrial fibrillation 100 (25%) 63 (36%) 51 (36%) 56 (38%) .00034
LVEF (%) 55  13 52  14 47  16 50  14 .0001
LVEDD (cm) 5.4  0.7 5.5  0.9 5.5  0.9 5.5  0.9 .606
LVESD (cm) 3.6  0.8 3.9  0.1 4.1  0.1 4.1  0.1 .0001
LA diameter (cm) 4.4  0.8 4.6  0.9 4.8  0.7 5.0  0.8 .0001
RV dysfunction 19 (5%) 22 (13%) 43 (30%) 53 (36%) .0001
MR grade 3.5  0.7 3.2  0.8 3.4  0.8 3.6  0.6 .0003
TR grade 0.6  0.8 1.05  0.9 1.4  1.1 1.8  1.3 <.0001
AI grade 0.2  0.7 0.4  1 0.5  1 0.6  1 .0002
Severe AS 10 (2%) 8 (5%) 16 (11%) 15 (10%) <.0001
Chronic lung disease 36 (9%) 28 (16%) 21 (15%) 30 (21%) .0021
Redo operation 21 (5%) 11 (6%) 12 (8%) 17 (11%) .0625
Diabetes mellitus 45 (11%) 37 (21%) 27 (19%) 48 (32%) .0001
Hypertension 225 (55%) 122 (69%) 100 (70%) 114 (77%) .0001
Peripheral arterial disease 20 (5%) 8 (5%) 13 (9%) 17 (11%) .041
History of stroke 30 (7%) 19 (11%) 21 (15%) 16 (11%) .071
Previous MI 41 (10%) 36 (20%) 30 (21%) 31 (21%) .0003
Cerebrovascular disease 44 (11%) 24 (14%) 25 (18%) 29 (20%) .031
Renal failure (dialysis) 6 (1%) 6 (3%) 18 (13%) 20 (14%) .0001
ACE inhibitors/ARB 161 (40%) 70 (40%) 76 (54%) 64 (43%) .0284
Beta-blockers 176 (43%) 96 (56%) 85 (60%) 91 (61%) .0009
Data presented in mean  SD or n (%). AI, Aortic insufficiency; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; AS, aortic stenosis; BMI, body mass
index; LA, left atrium; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-diastolic diameter; MI, myocardial
infarction; MR, mitral regurgitation; NYHA, New York Heart Association; RV, right ventricle; sBP, systemic blood pressure in systole; SD, standard deviation; sPAP, systolic
pulmonary artery pressure; TR, tricuspid regurgitation. *PH absent: sPAP< 40 mm Hg; mild PH: 40  sPAP< 50 mm Hg; moderate PH: 50  sPAP< 60 mm Hg; severe
PH: sPAP  60 mm Hg. yMorbid obesity: BMI  40 kg/m2.
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3% for patients with mild PH (40  sPAP<50 mm Hg),
8% for moderate PH (50  sPAP < 60 mm Hg), and
12% for those with severe preoperative PH (sPAP  60
mm Hg) (P<.0001) (Figure 2). By multivariable analysis,
preoperative sPAPwas a predictor associated with operative
mortality (Table 5).
Major operative morbidity for the entire group included
new-onset atrial fibrillation (121, 14%), dialysis (31,
3.5%), stroke (19, 2%), and sepsis (22, 2.5%). Higher pre-
operative sPAPs were associated with higher rates of post-
operative sepsis, prolonged ventilation, and dialysis
(Table 4). On comparison of patients with no PH
(sPAP < 40 mm Hg) with those with mild PH (40 
sPAP<50 mm Hg), morbidity, including renal failure (di-
alysis) (P ¼ .8), atrial fibrillation (P ¼ .24), and stroke
(P ¼ .8), was not significantly different. However, pro-
longed ventilation (no PH: 43 [11%] vs mild PH: 441442 The Journal of Thoracic and Cardiovascular Sur[25%], P < .0001) and longer hospital stay (median 5
days for no PH vs 8 days for mild PH, P<.0001) and inten-
sive care unit stay more than 24 hours (no PH: 13 [3%] vs
mild PH 10 [6%], P ¼ .0244) were more common in pa-
tients with mild PH (Table 4).
Late Survival
Actuarial survival in patients without PH (sPAP<40 mm
Hg) at 1, 3, 5, and 7 years was 96%, 92%, 86%, and 84%,
respectively, compared with 83%, 73%, 67%, and 61%,
respectively, for those with preoperative PH (sPAP  40
mmHg) (P<.00279) (Figure 3, A). Long-term survival pro-
gressively decreased with increasing preoperative sPAP
grade (P<.0001) (Figure 3, B). In a Cox proportional haz-
ards analysis, increasing preoperative sPAP was associated
with decreased long-term survival (Table 6). Among pa-
tients with no or minimal preoperative symptoms (380
[43%]) (NYHA class I: 88 [10%], NYHA class II: 292gery c December 2011
TABLE 3. Operative characteristics for 873 patients undergoing
mitral valve operation for mitral regurgitation
Characteristic No. (%), or mean ± SD
MVoperation
Repair 747 (86%)
Replacement 126 (14%)
MV pathology
Degenerative MR due to leaflet
prolapse
389 (44%)
Anterior leaflet prolapse 52 (13%)
Posterior leaflet prolapse 270 (70%)
Bileaflet prolapse 67 (17%)
Isolated annular dilation (type I) or
functional (type IIIb  type I)
271 (31%)
Rheumatic 70 (8%)
Endocarditis 132 (15%)
Paravalvular leak 8 (1%)
Prosthetic valve degeneration 3 (1%)
Redo operation 61 (7%)
Concomitant procedures
Coronary artery bypass 253 (29%)
TVoperation 133 (15%)
AVoperation 100 (11%)
CryoMaze procedure 185 (21%)
ASD closure 22 (3%)
Perfusion time (min)
Mean 126  49
Median 117
Crossclamp time (min)
Mean 97  37
Median 94
Operative mortality 43 (5%)
AV,Aortic valve; ASD, atrial septal defect;MR,mitral regurgitation;MV,mitral valve;
SD, standard deviation; TV, tricuspid valve.
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sPAP<50 mm Hg) compromised long-term survival (log
rank, P ¼ .0004). Among those 373 patients with sPAP de-
termined with both echocardiography and RHC, we found
that echocardiographic-derived sPAP was similarly predic-
tive of late mortality as was sPAP determined by RHC
(echocardiographic-derived sPAP: HR, 1.024 per 1 mm
Hg increment; 95% CI, 1.011–1.034; P ¼ .0004 vs RHC-
derived sPAP: HR, 1.029 per 1 mm Hg increment; 95%
CI, 1.0117–1.041; P<.0001).
Even after excluding patients with a history of myocar-
dial infarction (n ¼ 138), concomitant aortic valve surgery
(n ¼ 100), or coronary artery bypass surgery (n ¼ 253), pa-
tients with sPAP 40 mm Hg or greater had higher operative
mortality and long-term death (Appendix 2).
Analysis of Outcomes Based on the Ratio of Systolic
Pulmonary Artery Pressure to Systemic Blood
Pressure
On the basis of the ratio of systolic pulmonary to systolic
systemic blood pressure, patients were categorized asThe Journal of Thoracic and Carhaving no PH (sPAP/sBP< 0.3) (n ¼ 387, 45%), mild
PH (0.3  sPAP/sBP< 0.4) (n ¼ 200, 23%), moderate
PH (0.4  sPAP< 0.5) (n ¼ 143, 16%), and severe PH
(sPAP/sBP  0.5) (n ¼ 143, 16%). Operative mortality
was 2% (n ¼ 8) for no PH, 4% (n ¼ 8) for mild PH,
6.3% (n¼ 9) for moderate PH, and 13% (n¼ 18) for severe
PH (P<.0001). Long-term survival decreased significantly
with increased preoperative sPAP/sBP ratio (Appendix
Figure 1). These findings were nearly identical to those in
which only isolated sPAP was used as a predictor.
Isolated Degenerative Mitral Regurgitation
Overall, 284 patients with isolated degenerative MR with
leaflet prolapse were studied in cohort 2. The mean age was
57  13 years, and the mean sPAP was 36  14 mm Hg
(Table 7). Preoperative sPAP was measured using RHC in
214 patients (75%). Preoperatively, 193 patients (68%)
had no PH (sPAP< 40 mm Hg), 48 patients (17%) had
mild PH (40  sPAP < 50 mm Hg), and 43 patients
(15%) had moderate/severe PH (sPAP  50 mm Hg). Pre-
operative NYHA class III or IV symptoms were present in
121 patients (39%), and 173 patients (61%) had class I or II
symptoms. MV repair was performed in 277 patients
(98%), and MV replacement was performed in 8 patients
(2%). Concomitant procedures, including tricuspid valve
repair (n ¼ 18, 6%) and CryoMaze procedure (n ¼ 58,
20%), were more common in patients with PH (sPAP 
40 mm Hg). Operative mortality was 0.8% (2/284).
Kaplan–Meier analysis showed that survival decreased
with increasing preoperative PH grade (Figure 4). Overall
actuarial survival at 1, 3, and 5 years after MV surgery
was 99.5%, 98.5%, and 97.5%, respectively, in patients
with no PH (sPAP< 40 mm Hg) compared with 95.8%,
92.9%, and 91.2%, respectively, for those with mild PH
(40  sPAP < 50 mm Hg) and 90.6%, 84.2%, and
80.5%, respectively, for those with moderate to severe PH
(sPAP  50 mm Hg) (P ¼ .0002). Compared with patients
with no PH, 5-year survival decreased in patients with mild
PH (98%  1% for no PH vs 91%  4% for mild PH,
P ¼ .002). In a Cox proportional hazards analysis, factors
associated with decreased long-term survival included in-
creasing preoperative sPAP (HR, 1.037 per 1 mm Hg in-
crease; 95% CI, 1.004–1.066; P ¼ .0277), age (HR,
1.303; 95% CI, 1.051–1.625; P ¼ .0277), and left ventric-
ular ejection fraction (HR, 0.902; 95% CI, 0.854–0.956;
P ¼ .001) (C-statistic for the multivariable model ¼ 0.9).
Pulmonary Artery Pressure Changes After
Operation
The mean sPAP at different time points is demonstrated
in Figure 5, A. In the entire population, mean sPAP de-
creased modestly from 43  16 mm Hg before operation
to 39  11 mm Hg before hospital discharge (P<.0001).
Compared with the predischarge value, mean sPAP wasdiovascular Surgery c Volume 142, Number 6 1443
TABLE 4. Operative characteristics and hospital morbidity and mortality as a function of preoperative systolic pulmonary artery pressure*
Variable
sPAP<40 mm Hg
407 (47%)
40  sPAP<50 mm Hg
176 (20%)
50  sPAP<60 mm Hg
142 (16%)
sPAP  60 mm Hg
148 (17%) P value
CVPy (mm Hg) 10  5 12  5 13  6 15  6 <.001
MV pathology
Degenerative (leaflet prolapse) 240 (59%) 70 (40%) 36 (25%) 43 (29%) <.0001
Isolated annular dilation (type I) or
functional (type IIIb  type I)
90 (22%) 62 (35%) 66 (46%) 53 (36%) <.001
Rheumatic 21 (55%) 13 (7%) 13 (9%) 23 (16%) .001
Endocarditis 51 (13%) 31 (18%) 25 (18%) 25 (17%) .282
MV repair 373 (92%) 154 (88%) 117 (82%) 103 (70%) <.0001
Concomitant procedure
Coronary artery bypass 89 (22%) 51 (29%) 56 (39%) 57 (39%) <.0001
TVoperation 21 (5%) 29 (16%) 30 (21%) 50 (34%) <.0001
AVoperation 27 (7%) 22 (13%) 23 (16%) 28 (19%) .0001
CryoMaze procedure 71 (17%) 53 (30%) 30 (21%) 31 (21%) .0008
Operative mortality 7 (2%) 6 (3%) 12 (8%) 18 (12%) <.0001
Morbidity
Renal failure (dialysis) 8 (2%) 4 (2%) 9 (6%) 10 (7%) .0094
Prolonged ventilation 43 (11%) 44 (25%) 35 (25%) 54 (36%) <.0001
Sepsis 7 (2%) 1 (1%) 4 (3%) 10 (7%) .0022
Atrial fibrillation 46 (11%) 26 (15%) 27 (19%) 22 (15%) .12
Stroke 8 (2%) 3 (2%) 4 (3%) 4 (3%) .31
Length of stay
ICU>24 h 13 (3%) 10 (6%) 8 (6%) 12 (8%) .021
LOS (median [25th–75th], d) 5 (4–9) 8 (6–16) 11.5 (7–19) 12 (8–22) <.0001
AV,Aortic valve; CVP, central venous pressure; ICU, intensive care unit; LOS, length of stay;MV,mitral valve; sPAP, systolic pulmonary artery pressure; TV, tricuspid valve. *PH
absent: sPAP<40 mm Hg; mild PH: 40  sPAP<50 mm Hg; moderate PH: 50  sPAP<60 mm Hg; Severe PH: sPAP  60 mm Hg. yIntraoperative, before incision.
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Hg, P ¼ .907) and after 2 years of follow-up (38  13 mm
Hg, P¼ .952) (Figure 5, A). Figure 5, B, demonstrates sPAP
at different time points for each category of pulmonary ar-
tery pressure. Compared with preoperative values, sPAP de-
creased on predischarge echocardiography in all categories
except in patients with no PH where there was a small in-
crease. The relative decrease was most pronounced in pa-
tients with preoperative moderate (50  sPAP< 60 mm
Hg) and severe PH (sPAP  60 mm Hg). On late follow-FIGURE 2. Hospital mortality according to preoperative PH grade
(P<.0001). PH, Pulmonary hypertension.
1444 The Journal of Thoracic and Cardiovascular Surup, sPAP was similar to predischarge levels. Residual PH
(sPAP  40 mm Hg) was more commonly present among
patients with mild (40  sPAP< 50 mm Hg), moderate
(50  sPAP< 60 mm Hg), or severe degree (sPAP  60
mm Hg) of preoperative PH (Figure 5, B and C). Of 159 pa-
tients who had preoperative sPAP 50 mm Hg or greater and
follow-up echocardiographic data available, 56 (35%) still
had sPAP 50 mm Hg or greater 2 years (mean, 714  603
days) after surgery.DISCUSSION
Principal Findings
This article presents early and late outcomes after MV
surgery in a large series of patients with MR accordingTABLE 5. Predictors of operative mortality*
Variable OR 95% CI P
sPAP (per 1 mm Hg increment) 1.023 1.003–1.044 .0270
NYHA functional class III–IV 3.442 1.040–1.410 .0052
Age (per unit) 1.034 1.007–1.064 .0159
Concomitant CABG 2.133 1.041–4.464 .0395
Dialysis 4.451 1.068–1.785 .0018
IE 3.017 1.204–7.407 .0194
RV dysfunction 3.178 1.552–6.488 .0017
CABG, Coronary artery bypass graft; CI, confidence interval; IE, infective endocar-
ditis; NYHA, New York Heart Association; OR, odds ratio; RV, right ventricle;
sPAP, systolic pulmonary artery pressure. *C-statistic ¼ 0.854.
gery c December 2011
FIGURE 3. Long-term survival according to preoperative PH. A, Actuarial survival according to a cutoff value of sPAP 40 mm Hg or greater. B, Survival
according to preoperative PH grade. PH, Pulmonary hypertension; sPAP, Systolic pulmonary artery pressure.
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measured in the majority of patients with RHC. On the ba-
sis of the cutoff point of preoperative sPAP 40 mm Hg or
greater, PH was observed in more than half of the popula-
tion. Compared with patients with no PH (sPAP<40 mm
Hg), patients presenting with mild PH (40  sPAP< 50
mm Hg) had lower left ventricular ejection fractions,
more atrial fibrillation and more tricuspid regurgitation.
Operative mortality among patients with no PHThe Journal of Thoracic and Car(sPAP < 40 mm Hg) was low (2%). With increased
sPAP 40 mm Hg or greater or sPAP/sBP 0.3 or greater,
higher mortality and morbidity were observed after sur-
gery. Long-term survival was compromised by the pres-
ence of any degree of preoperative PH, including those
patients with mild PH (40  sPAP< 50 mm Hg). These
findings were also evident in patients with isolated degen-
erative MR. Pulmonary artery pressures declined immedi-
ately after operation but not thereafter, and residual PHdiovascular Surgery c Volume 142, Number 6 1445
TABLE 6. Predictors of long-term mortality*
Variable HR 95% CI P
sPAP (per 1 mm Hg increment) 1.018 1.007–1.028 .001
NYHA function class (III /IV vs I/II) 1.835 1.216–2.844 .0034
Age (per unit) 1.036 1.021–1.051 <.0001
Dialysis (yes vs no) 3.052 1.596–5.452 .0013
Diabetes (yes vs no) 1.826 1.222–2.688 .0037
CI,Confidence interval;HR, hazard ratio;NYHA,NewYork Heart Association; sPAP,
systolic pulmonary artery pressure. *C-statistic of multivariable model: 0.764.
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Dwas observed late among all patients except those with
normal preoperative sPAP(s).
The prevalence of PH in patients undergoing surgery for
MR depends on the threshold of sPAP used to define PH. Al-
though the cutoff value of sPAP to define PH (sPAP> 50
mm Hg) in current guidelines is derived from small clinical
series performed on patients with systemic sclerosis,18 var-
ious values are frequently used in practice.8,19,20 We used
a lower threshold of sPAP value (sPAP  40 mm Hg)
compared with existing guidelines to identify individuals
at risk for adverse outcomes after surgery. Outcomes after
surgery for patients with no PH (sPAP<40 mm Hg) were
excellent. Operative mortality was 2%, and 86% survived
more than 5 years after surgery. However, approximately
1 of 10 patients with severe PH (sPAP  60 mm Hg)TABLE 7. Baseline characteristics of the patients with isolated leaflet pr
hypertension*
Variable
sPAP<40 mm Hg
193 (68%)
40
sPAP (mm Hg)
Mean  SD 28  6
Median (25th–75th percentile) 29 (25–33)
Age (y) 55  12
Female gender 60 (31%)
BMI (kg/m2, mean  SD) 26  6
Morbid obesityy 5 (39%)
NYHA class III/IV 57 (30%)
Atrial fibrillation 38 (20%)
LVEF (%) 58  8
LVEDD (cm) 5.5  0.7
LVESD (cm) 3.4  0.7
LA diameter (cm) 4.5  0.7
RV dysfunction 3 (2%)
MR grade 3.7  0.5
TR grade 0.4  0.6
Chronic lung disease 0 (0%)
Diabetes mellitus 5 (3%)
Hypertension 88 (46%)
History of stroke 2 (1%)
Previous MI 1 (1%)
Renal failure (dialysis) 0 (0%)
Data presented in mean SD or n (%).BMI,Bodymass index;LA, left atrium;LVEF, left ve
ventricular end-diastolic diameter;MI,myocardial infarction;MR,mitral regurgitation; NY
pressure; TR, tricuspid regurgitation. *PH absent: sPAP<40 mm Hg; mild PH: 40 sPAP<
yMorbid obesity: BMI  40 kg/m2.
1446 The Journal of Thoracic and Cardiovascular Surundergoing surgery for MR died in hospital or early after
surgery, and only half survived 5 years after surgery.
Long-term survival in patients with isolated degenerative
MR was compromised among patients with any degree of
preoperative PH.
In both cohorts in this study, preoperative sPAP was an
important independent predictor for long-term survival af-
ter surgery. Even the presence of mild PH (40 
sPAP< 50 mm Hg) compromised long-term survival in
both cohorts. These results support a management strategy
of surgical intervention for MR before the sPAP reaches 50
mm Hg. Le Tourneau and colleagues2 studied 256 patients
with organic MR referred for MV surgery. Preoperative PH
(sPAP  50 mm Hg) was present in 83 patients. Although
PH did not significantly increase operative mortality, sur-
vival 8 years after surgery was 86% in patients with no
PH compared with 58% in those with sPAP 50 mm Hg or
greater. Patients with preoperative PHwere more symptom-
atic early after surgery and had more left ventricular dys-
function compared with those with no PH. Le Tourneau
and colleagues2 found that long-term risk for mortality in-
creased by 50% per 10 mm Hg increase in preoperative
sPAP.2 Barbieri and colleagues7 studied 437 patients with
degenerative severe MR with flail leaflet. All patients had
no or minimal symptoms with normal left ventricularolapse (n ¼ 284) according to the degree of preoperative pulmonary
 sPAP<50 mm Hg
48 (17%)
50 mm Hg  sPAP
43 (15%) P value
44  3 63  13 <.0001
44 (40–46) 59 (51–70)
65  14 62  13 .001
19 (40%) 22 (51%) .0370
27  6 30  8 .0045
2 (15%) 6 (46%) .445
27 (56%) 27 (63%) <.0001
19 (40%) 13 (30%) .0109
56  8 55  11 .0414
5.6  0.7 5.6  0.8 .5551
3.7  0.8 3.8  0.8 .0088
4.8  0.7 4.9  0.7 .0020
3 (6%) 7 (16%) .0001
3.4  0.7 3.6  0.5 .0207
1.0  1.0 1.4  1.1 <.0001
0 (0%) 0 (0%) –
4 (8%) 7 (16%) .0013
30 (63%) 27 (63%) .0275
0 (0%) 3 (7%) .0149
2 (4%) 1 (2%) .1359
0 (0%) 1 (2%) .0601
ntricular ejection fraction; LVEDD, left ventricular end-diastolic diameter;LVESD, left
HA,New York Heart Association; RV, right ventricle; sPAP, systolic pulmonary artery
50 mm Hg; moderate PH: 50  sPAP<60 mm Hg; Severe PH: sPAP 60 mm Hg.
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FIGURE 4. Survival curve according to preoperative PH (sPAP 40 mm
Hg) in cohort 2 (patients with isolated degenerative MR due to flail leaflet).
For all patients (A) and according to preoperative PH grade (B).MR,Mitral
regurgitation; PH, pulmonary hypertension; sPAP, systolic pulmonary ar-
tery pressure.
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Dfunction. Baseline PH (sPAP>50 mm Hg) was present in
23% of patients. Actuarial survival 5 years after surgery
was 86% in patients with no PH (sPAP<50 mm Hg) com-
pared with 63% in those with PH (sPAP>50 mm Hg). MV
surgery was eventually performed in 75% of patients. Post-
operative survival was significantly decreased in patients
with baseline sPAP 50 mm Hg or greater.7 The authors con-
cluded that PH (sPAP>50 mmHg) in patients with chronic
organicMR carries an increased risk of long-termmortality,
which is similar to our experience.2 They found that MV
surgery is beneficial to improve sPAP, but surgery cannot
completely abolish adverse effects of PH on outcomes.7
Studies have shown that sustained systemic hypertension
correlates with higher values of pulmonary artery pres-
sures21 and suggested that interpretation of sPAP in hyper-
tensive patients should take into account sBP value.21 WeThe Journal of Thoracic and Carstudied the pulmonary artery to systemic blood pressure
in our population and found nearly identical results to our
initial analysis that examined only sPAP. We found that el-
evated sPAP/sBP ratio (sPAP/sBP 0.3) compromised both
early and late survival after MV surgery for MR.
No Pulmonary Hypertension Versus Mild Pulmonary
Hypertension: Lessons Learned
Operativemortality andmajor morbidity were similar be-
tween patients with no PH (sPAP<40 mm Hg) and those
with mild PH (40  sPAP< 50 mm Hg). However, long-
term survival was lower in patients with mild PH compared
with patients with no preoperative PH in the overall study
population, in the cohort with isolated leaflet prolapse,
and in patients with no or minimal preoperative symptoms.
Given the increased risk of adverse outcomes in patients
with mild PH (40  sPAP< 50 mm Hg) compared with
those with no PH (sPAP<40 mm Hg), we believe that re-
ferral for MV surgery for MR should be considered before
sPAP exceeds 40 mm Hg.
Regression of Pulmonary Artery Pressures After
Mitral Valve Surgery
In this study, significant reduction in mean sPAP was ob-
served early after operation. During follow-up, the mean
sPAP failed to return to normal levels in patients with any de-
gree of preoperative PH (sPAP 40mmHg). Incomplete im-
provement in pulmonary artery pressures after operation for
MR suggests that significant pulmonary vascular disease de-
velops early in the presence of MR, and therefore a manage-
ment strategy that triggers operative intervention when the
sPAP exceeds 40 mm Hg will improve long-term survival.
Study Limitations
The present study was subject to the limitations inherent
in a retrospective study. We did not exclude patients with
aortic valve disease or chronic obstructive pulmonary dis-
ease in the first cohort. Although we performed multivari-
able analysis to account for confounding factors, we
cannot guarantee that unmeasured confounding factors
did not influence our results. Preoperative evaluation of pul-
monary pressures was comprehensive, although predis-
charge and follow-up echocardiographic data were
incomplete. We did not have data to evaluate the impact
of residual PH on other outcomes, such as freedom from
heart failure, atrial fibrillation, or NYHA function class at
follow-up. Medical therapy after surgery was not assessed
and might affect long-term outcomes.
CONCLUSIONS
PH is a common adverse sequela of MR. Systolic pulmo-
nary artery pressure is a predictor of operative mortality,
morbidity, and long-term death. Even mild PH (40 
sPAP < 50 mm Hg) compromises outcomes after MVdiovascular Surgery c Volume 142, Number 6 1447
FIGURE 5. Mean sPAP at different time points. A, All patients (mean standard deviation sPAP at preoperative: 43 16, predischarge: 39 11, follow-
up<2 years: 39  12, follow-up>2 years: 38  13 mm Hg). B, According to PH grade for all patients. C, For 404 patients with 2-year follow-up. Mean
sPAP decreased markedly in patients with higher preoperative sPAP, but residual sPAP 40 mm Hg or greater was more common after surgery and during
follow-up in these groups. Pulmonary pressures at predischarge relatively correlate with the late response of pulmonary pressure changes to surgery (no
significant difference was identified in mean sPAP at predischarge and within 2 years follow-up, P ¼ .95). UMedian: 12 months (24 days to 24 months).
xMedian: 41 months (24–91 months). *P<.01 compared with preoperative value. MR,Mitral regurgitation; PH, pulmonary hypertension; sPAP, Systolic
pulmonary artery pressure.
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Ghoreishi et al Acquired Cardiovascular Diseasesurgery for MR. sPAP improved early after surgery, al-
though residual PH was commonly observed among all pa-
tients except thosewith normal preoperative sPAP (<40mm
Hg). Referral for MV surgery for MR should be considered
in the presence of an sPAP 40 mm Hg or greater.APPENDIX FIGURE 1. Kaplan–Meier survival curve according to pre-
operative sPAP/sBP. sPAP, Systolic pulmonary artery pressure; sBP, systolic
blood pressure.
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APPENDIX 1. VARIABLES USED IN ANALYSIS
Demographics: age (y), gender, sex, weight (kg), height
(cm), body mass index (kg/m2), NYHA function class
(I–IV), emergency operation.
Cardiac stricture and function: left ventricular ejection
fraction (%), sPAP (mm Hg), left ventricular inner systolic
diameter (cm), left ventricular inner diastolic diameter
(cm), LA diameter (cm), right ventricular dysfunction
(0¼ no, 1¼ yes), MV regurgitation, aortic valve regurgita-
tion, aortic valve stenosis, tricuspid valve regurgitation.
Cardiac comorbidity: number of coronary vessels with
>50% stenosis, left main coronary disease 50% stenosis,
atrial fibrillation. ventricular arrhythmia, family history of
coronary artery disease, dyslipidemia, heart failure, hyper-
tension, preoperative pacemaker, previous myocardial
infarction, endocarditis.
Noncardiac morbidity: diabetes, chronic obstructive pul-
monary disease, peripheral arterial disease, dialysis, stroke,
smoking.
Procedures: MV repair/replacement, tricuspid valve sur-
gery, aortic valve repair/replacement, coronary artery bypass
grafting, surgical ablation for atrial fibrillation, reoperation.
APPENDIX 2. ANALYSIS OF OUTCOMES FOR
ISOLATED MITRALVALVE OPERATION FOR
MITRAL REGURGITATION
Patients with previous myocardial infarction (n ¼ 138),
concomitant aortic valve surgery (n ¼ 100), and coronary
artery bypass surgery (n ¼ 253) were excluded, leavingdiovascular Surgery c Volume 142, Number 6 1449
APPENDIX FIGURE 3. Long-term survival according to preoperative
PH among patients who underwent isolated MV operation for MR
(n ¼ 478). PH, Pulmonary hypertension.
APPENDIXFIGURE 2. Hospital mortality according to preoperative PH
grade among patients who underwent isolated MV operation for MR
(n ¼ 478). PH, Pulmonary hypertension.
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D478 patients for analysis. Patients were categorized as hav-
ing no PH (sPAP<40 mm Hg) (n ¼ 277, 58%), mild PH
(40  sPAP< 50 mm Hg) (n ¼ 91, 19%), moderate PH
(50  sPAP< 60 mm Hg) (n ¼ 53, 11%), or severe PH
(sPAP 60 mmHg) (n¼ 57, 12%). Overall operative mor-
tality was 2.3% (n ¼ 11). Operative mortality (AppendixAPPENDIX TABLE 1. Predictors of early and late mortality for 478
regurgitation
Predictor
Univariate analysis
OR 95% CI
Early mortality
sPAP (per 1-mm increase) 1.063 1.0319–1.0981
NYHA (III/IV vs I/II) 4.923 1.252–35.57
TV surgery 4.280 1.0929–14.923
Dialysis 19.955 4.761–76.92
History of stroke 6.099 1.545–21.141
Late mortality HR
sPAP (per 1-mm increase) 1.0533 1.0374–1.0687
Gender (male vs female) 2.0256 1.1133–3.7900
NYHA (III/IV vs I/II) 4.3928 2.2036–9.7415
Age (per year) 1.0291 1.0072–1.05179
LV ejection fraction 1.0345 1.0105–1.0563
LA dimension (cm) 1.0459 1.0059–1.0855
TR grade 1.6174 1.3124–1.9701
MV replacement 3.2775 1.5792–6.2936
TV surgery 2.6871 1.2953–5.1547
RV dysfunction 3.3092 1.4909–6.6058
Diabetes 3.0498 1.50663–5.7724
Hypertension 2.255 1.206–4.465
Infective endocarditis 3.3201 1.7900–6.0237
Chronic lung disease 3.1836 14897–6.2100
Peripheral arterial disease 4.1319 1.2934–10.7091
History of stroke 3.6746 1.809–6.979
Atrial fibrillation 2.0265 1.0936–3.6734
Emergency operation 6.099 1.545–21.141
CI, Confidence interval; LA, left atrial; LV, left ventricle; MV, mitral valve; NYHA, New Y
artery pressure; TR, tricuspid regurgitation; TV, tricuspid valve.
1450 The Journal of Thoracic and Cardiovascular SurFigure 2) and long-term death (Appendix Figure 3) were
significantly higher among patients with higher preopera-
tive sPAP. Preoperative sPAP (per 1-mm increase) was an
independent predictor for both operative mortality and
long-term death (Appendix Table 1).patients who underwent isolated mitral valve operation for mitral
Multivariate analysis
P OR 95% CI P
.0001 1.0585 1.013–1.087 .0018
.0207
.0381
.0002 10.34 2.347–41.66 .0033
.0124
HR
<.0001 1.0387 1.021–1.056 <.0001
.0206
<.0001 2.46 1.193–5.635 .0138
.0086 1.059 1.0327–1.0877 <.0001
.0059 1.028 1.002–1.0537 .0373
.0242
<.0001 1.470 1.152–1.859 .0023
.0023
.0096
.0048
.0028
.0102
.0002 9.651 4.127–22.901 <.0001
.0041 2.280 1.051–4.544 .0379
.0211
.0006
.0255
.0124
ork Heart Association; OR, odds ratio; RV, right ventricle; sPAP, systolic pulmonary
gery c December 2011
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Dr Gerald Lawrie (Houston, Tex). This is a large series of pa-
tients, the biggest reported to date, and it also includes the
broader spectrum of severity of disease of any previous report.
It is also unique in that many of the patients had their PH diag-
nosed by RHC. Up to 40% of patients in previous studies have
been excluded because insufficient tricuspid regurgitation has
been present to allow them to assess pulmonary artery pressure
by echocardiography.
This study has confirmed the findings of smaller earlier studies
that an sPAP greater than 50 mm is a strong independent predictor
of early and late survival. This study also demonstrated that in all
categories of PH, regression of PH is incomplete after surgery,
reaching approximately 40 mm systolic after 2 years. Despite
the fact that surgery improves the prognosis at all levels of pulmo-
nary artery pressure, regression is incomplete because the PH seen
in severe MR arises not only from the MR itself but also from a se-
ries of complex changes in the left ventricle and LA morphology
and their systolic and diastolic function. The pulmonary artery
bed may develop increased vascular tone, and some degree of pul-
monary hypertensive vasculopathy may develop as seen in mitral
stenosis. Some of these changes, once present, may not regress de-
spite relief of the MR.
These findings and those of this study suggest it may be impor-
tant to pursue the issue of PH more aggressively and specifically
than we have done to date.
First, these data provide further strong support for surgery early
after the diagnosis of asymptomatic severe MR. Intraoperatively,
improvement of LA function by atrial fibrillation ablation and vol-
ume reduction surgery could benefit, and I think we need to look
more carefully at the influence of surgery on left ventricular dia-
stolic function to try to refine our techniques to preserve left ven-
tricular and LA function.
In patients presentingwith PH in the 60 to 80mm range, we have
formanyyears involved our pulmonologists early preoperatively to
evaluate andmanage the PH and exclude other contributory causes.
It is noteworthy that 21% of the patients in this study with pulmo-
nary artery pressures greater than 60 had significant chronic ob-
structive pulmonary disease. It may be that this pulmonary
evaluation should be extended to include RHC in all cases with
drug evaluation for pulmonary artery vascular responsiveness.
Because incomplete regression of the pulmonary artery pres-
sure was still present 2 years after surgery, it also may be that these
patients should be followed long-term by a pulmonologist, some-
thing we have not done, and a cardiologist. Long-term pulmonary
artery drug therapy could be beneficial in some cases.
Thank you for this excellent presentation, which I think has
brought a neglected topic to our attention. I do have 2 questions
for the presenter.
What proportion of the patients with no tricuspid regurgitation
on echo had RHC showing significant PH? Do you think that all
patients undergoing mitral repair with no TR should have RHC
to assess their pulmonary artery pressure before they go to sur-
gery? The second question relates to the fact that you agree we
have a big problem here that we have neglected and that the ap-
proach to the care of these patients with persistent significant PH
should involve long-term follow-up with a pulmonologist with ac-
tive treatment to moderate their PH.The Journal of Thoracic and CarDr Ghoreishi. To respond to your first question, we could
not assess the sPAP based on echocardiography because of
an absent tricuspid regurgitation jet velocity in 15% of pa-
tients. Among these patients, sPAPs were greater than 40 in
37% as measured on RHC. In 373 patients who were studied
with both echocardiography and RHC, we found a reasonably
good correlation between the results of echo and RHC, al-
though there was significant variability. We expect some dis-
crepancies between measurement of sPAP with RHC and
echocardiography. Pulmonary artery pressures are dynamic,
and the echocardiography and RHC were performed at differ-
ent times.
We believe that the current recommendation to operate after the
sPAP exceeds 50 mm Hg is associated with compromised early
and late outcomes, and therefore we are recommending moving
that threshold back to 40 mm Hg.
We advocate RHC for patients with asymptomatic severe MR
who are managed nonsurgically to make sure that PH (sPAP 
40 mm Hg) is not present.
To respond to your second question, we currently do not have
any therapeutic protocols directed at residual PH. We found that
during follow-up, sPAP in patients with preoperative PH (sPAP
 40 mm Hg) never decreased to normal after surgery. We agree
with you that these patients may benefit from long-term pharmaco-
logic treatment after surgery and follow-up with a multidisciplin-
ary team including a pulmonologist, but currently we don’t have
a protocol for these patients.
Dr Thierry Mesana (Ottawa, Ontario, Canada). Congratula-
tions for this large and interesting study. I noticed you had 12%
mortality in those with high severe PH, and you basically had al-
most no mortality in the patients with leaflet prolapse. Does this
mean that most of your mortality was in the patients without or-
ganic disease, such as ischemic patients?
Dr Ghoreishi. The number of patients with severe PH was low
in patients with degenerative MR. In the entire group, more than
30% of patients had moderate or severe PH, and patients with
higher degrees of preoperative PH were more likely to have func-
tional and rheumatic MV disease.
Dr Mesana. Patients with severe PH may not have the same
level of PH at the time of operation. So when did you take
your measurements to consider the patient as having severe
PH? You can have a patient with a pulmonary systolic pressure
of 60 before surgery, going down to 40 during anesthesia, and
it is the same patient. So when did you qualify the patient with
severe PH?
Dr Ghoreishi. Determination of the presence and degree of PH
in this study was based completely on preoperative evaluation, not
intraoperative assessment.
Dr Chitwood. No Swan–Ganz?
Dr Ghoreishi. No.
Dr Mesana. No Swan–Ganz in the operating room?
Dr Ghoreishi. We routinely measure the pulmonary artery
pressure intraoperatively, but the results in this study are based
on catheterization-derived SPAP performed preoperatively.
Dr Chaw-Chi Chiu (Kaohsiung, Taiwan). You didn’t mention
the diastolic pulmonary artery pressure in your presentation. As
we know, elevated diastolic pulmonary artery pressure is impor-
tant to evaluate the reversibility of PH after the operation.diovascular Surgery c Volume 142, Number 6 1451
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DUsually, if the differences between the diastolic pulmonary artery
and the left ventricular end-diastolic pressures are more than 10
mm Hg, it would mean irreversibility of the PH even after the op-
eration. I would like to suggest measuring the diastolic pulmo-
nary pressure before operation to evaluate if the PH will
decrease after operation.
Dr Dan Lindblom (Stockholm, Sweden). I am currently work-
ing in Africa on different humanitarian projects, mainly in Sudan
on a big project where we are doing a lot of valve surgery. Last
year, we performed more than 600 MV procedures, obviously
mainly for mitral stenosis in young patients. More than half of
our patients came to surgery with a pulmonary pressure more1452 The Journal of Thoracic and Cardiovascular Surthan 60 mm Hg, and supersystemic pulmonary pressures were
not uncommon.
In your experience, do you have any cutoff line where you
would refuse the patient for surgery because of extreme PH?
What precautions would you take if you have a patient with very
high pulmonary pressures?
Dr Ghoreishi. Twenty-five patients in this study had an sPAP
greater than 80 mm Hg, and operative mortality was significantly
higher (17%) among those patients. However, we do not have any
absolute cutoff point to refuse surgery because a good number of
patients with significant PH can expect some symptomatic benefit
from operation.gery c December 2011
